Foghorn Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $16,072 | $3,267 | $9,247 | $8,153 |
Gross Profit | 16,072 | 3,029 | 8,445 | -11,849 |
EBITDA | -6,991 | -19,637 | -20,862 | -14,997 |
EBIT | -7,191 | -19,875 | -21,664 | -15,849 |
Net Income | -7,191 | -19,875 | -21,664 | -15,849 |
Net Change In Cash | 16,072 | 3,267 | 9,247 | 8,153 |
Free Cash Flow | -18,953 | -25,266 | -22,271 | -18,860 |
Cash | 68,080 | 88,913 | 80,876 | 89,334 |
Basic Shares | 70,629 | 69,540 | 62,980 | 63,029 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $30,909 | $22,602 | $34,155 | $19,228 |
Gross Profit | 27,577 | 22,602 | 34,155 | 19,208 |
EBITDA | -70,951 | -97,165 | -90,749 | -113,816 |
EBIT | -74,283 | -100,285 | -94,200 | -117,137 |
Net Income | -74,283 | -86,620 | -98,426 | -108,873 |
Net Change In Cash | 30,909 | 22,602 | 34,155 | 19,228 |
Cost of Revenue | -48,947 | |||
Free Cash Flow | -86,149 | -101,312 | -119,330 | 192,402 |
Cash | 80,876 | 55,454 | 80,336 | 52,214 |
Basic Shares | 62,980 | 54,899 | 41,974 | 41,591 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.10 |
2026-03-31 | -$0.29 |
2025-12-31 | -$0.36 |
2025-09-30 | -$0.25 |